Regeneron Pharmaceuticals's EBIT per Share for the
three
months ended in Dec. 2023 was $10.25.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $37.56.
During the past 12 months, the average EBIT per Share Growth Rate of Regeneron Pharmaceuticals was -15.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 6.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 18.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 24.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Regeneron Pharmaceuticals's EBIT per Share or its related term are showing as below:
REGN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -121.7 Med: 15.5 Max: 53.7
Current: 6.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Regeneron Pharmaceuticals was 53.70% per year. The lowest was -121.70% per year. And the median was 15.50% per year.
REGN's 3-Year EBIT Growth Rate is ranked better than 53.95% of 1305
companies
in the Biotechnology industry
Industry Median: 3.2
vs REGN: 6.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (NAS:REGN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Regeneron Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 